Trial Profile
A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Mycophenolate mofetil (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- 05 Aug 2009 Status changed from active, no longer recruiting to completed.
- 21 May 2009 Primary endpoint 'Clinical response' has not been met.
- 21 May 2009 Status change from active, no longer recruiting to completed